Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Avacta Appoints Brian Hahn as Chief Financial Officer

LONDON and PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Brian Hahn as Chief Financial Officer (CFO).

Mr Hahn brings more than 25 years of senior financial and operations experience in the biopharmaceutical industry, including a 15-year tenure as CFO and Senior Vice President of GlycoMimetics, Inc., where he led the company’s 2014 initial public offering (IPO) on Nasdaq and the build-out of its finance, accounting, investor relations and corporate affairs functions.

He has worked with life science companies from early stages through product launch, has significant experience in dealing with US healthcare investors, having been involved in multiple IPOs, and has raised over $700 million in capital. He has broad experience in developing strategic plans, business development deals, building strong organizations and establishing strong accounting and control systems which ensure Sarbanes-Oxley compliance.

Mr Hahn currently serves as co-chairman of the BIO Finance and Tax Committee, as a co-chairman of the Steering Committee of the Washington, DC chapter of the Association for Bio Financial Officers (ABFO) and has also served on the Securities and Exchange Commissions’ Advisory Committee on Small and Emerging Companies. Prior to his 15-year tenure at GlycoMimetics, Mr. Hahn held roles of increasing financial leadership responsibility, including Executive Director of Finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), and earlier, Senior Accountant with Bering Truck Corporation.

He received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.

“Brian brings the ideal combination of deep public company experience and understanding of the biotechnology sector that Avacta needs at this transformative stage,” said Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta. “His strategic insight and track record of successful financial leadership in clinical-stage companies will be essential as we advance our promising pipeline and prepare for our next phase of growth, including our potential dual listing on the Nasdaq exchange.”

“What drew me to Avacta was not just the company’s innovative technology platforms. It also has a clear vision for revolutionizing cancer treatment through targeted therapies that improve outcomes for patients and their families,” commented Brian Hahn. “The company has built a strong foundation with its pre|CISION® and Affimer® platforms, and I look forward to leveraging my experience to help accelerate Avacta’s growth and strengthen its position in both the U.K. and U.S. capital markets.”

For further information from Avacta, please contact:

Avacta Group plc
Michael Vinegrad, Group Communications
Director
www.avacta.com
  
Peel Hunt (Nomad and Broker)
James Steel / Chris Golden / Patrick Birkholm
www.peelhunt.com

  
ICR Healthcare
Mary-Jane Elliott / Jessica Hodgson / Max Bennett
avacta@consilium-comms.com
  
Investor Contact
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com

  
Media Contact
Carly Scaduto
Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com

About Avacta www.avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.